Home > Personal Investment Vitae
Location: United States
Gender: Male
Asset investment style: Qualitative fundamental analysis
Market capitalization:
$7,880,477talentsVirtual portfolio value:
$4,914,951talentsNet overall return per annum:
19.12%AYA current rank order:
#17Asset investment philosophy:
Joseph Corr trades U.S. stocks with the top #301 to #500 positive alpha signals.
Top 10 profitable stock transactions since January 2020Strategy
| Symbol | Company | Buy | Sell | Share Volume | Return (%) | Profit ($) |
|---|---|---|---|---|---|---|
| SXTP | 60 Degrees Pharmaceuticals Inc. Common Stock | $0.15 | $1.34 | 110,866 | +793.33% | $131,931 |
| VATE | INNOVATE Corp. Common Stock | $0.53 | $4.14 | 31,377 | +681.13% | $113,271 |
| XBIOW | Xenetic Biosciences Inc. Warrants | $2.00 | $23.16 | 4,407 | +1,058.00% | $93,252 |
| RMBL | RumbleOn Inc. Class B Common Stock | $0.36 | $7.95 | 9,200 | +2,108.33% | $69,828 |
| LSCC | Lattice Semiconductor Corporation Common Stock | $6.97 | $48.04 | 1,387 | +589.24% | $56,964 |
| HZNP | Horizon Therapeutics Public Limited Company Ordinary Shares | $16.41 | $98.56 | 589 | +500.61% | $48,386 |
| TUEM | Tuesday Morning Corp. Common Stock | $0.12 | $0.69 | 74,858 | +475.00% | $42,669 |
| NTZ | Natuzzi S.p.A. | $2.21 | $11.92 | 4,376 | +439.37% | $42,491 |
| MRNS | Marinus Pharmaceuticals Inc. Common Stock | $1.94 | $11.62 | 2,308 | +498.97% | $22,341 |
| BBX | BBX Capital Corporation | $2.54 | $14.54 | 1,545 | +472.44% | $18,540 |
| Sum | $639,673 |
Top 10 current stock portfolio positions as of February 2026Strategy
| Symbol | Company | Price | Position | Capitalization |
|---|---|---|---|---|
| RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $28.28 | 662 | $18,721 |
| SILC | Silicom Ltd Ordinary Shares | $20.20 | 913 | $18,442 |
| NSSC | NAPCO Security Technologies Inc. Common Stock | $41.02 | 448 | $18,376 |
| QURE | uniQure N.V. Ordinary Shares | $24.70 | 728 | $17,981 |
| NUTX | Nutex Health Inc. Common Stock | $161.25 | 111 | $17,898 |
| INBX | Inhibrx Biosciences Inc. Common Stock | $82.23 | 216 | $17,761 |
| GRDN | Guardian Pharmacy Services Inc. Class A Common Stock | $32.37 | 547 | $17,706 |
| IDYA | IDEAYA Biosciences Inc. Common Stock | $34.06 | 514 | $17,506 |
| VRM | Vroom Inc. Common Stock | $20.35 | 859 | $17,480 |
| AEO | American Eagle Outfitters Inc. Common Stock | $24.65 | 709 | $17,476 |
| Sum | $179,347 |
Top 20 investors
Top 20 influencers
Top 20 followers
| #1 - #5 | #6 - #10 | #11 - #15 | #15 - #20 |
|---|---|---|---|
| @Bob Hessonwitz | @Vincent Bonsai | @Jack hsu | @Apple |
| @Will | @Darren | @AJ Yeh | @ZimboDave |
| @Luminoalgo | @Sandra Martinazzison | @MRCASH1991 | @Bloom789 |
| @Duke | @Mo | @Amy | @Andy Cheung |
| @TechBull22 | @Ru-Ting Yeh | @Syl_will | @George |
2018-06-11 07:44:00 Monday ET
Facebook, Apple, Amazon, Netflix, and Google (FAANG) have been the motor of the S&P 500 stock market index. Several economic media commentators contend
2023-03-07 11:29:00 Tuesday ET
Former Bank of England Governor Mervyn King provides his deep substantive analysis of the Global Financial Crisis of 2008-2009. Mervyn King (2017) &nb
2019-01-23 11:32:00 Wednesday ET
Higher public debt levels, global interest rate hikes, and subpar Chinese economic growth rates are the major risks to the world economy from 2019 to 2020.
2017-11-19 08:37:00 Sunday ET
In 2000, a former law professor at Harvard proposed establishing the Financial Product Safety Commission in order to protect consumer rights in the provisio
2018-12-03 10:40:00 Monday ET
Bank of England publishes its latest insights into the economic impact of Brexit on British real productivity, capital investment, and labor supply as of 20
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be